

# ForPatients

by Roche

Idiopathic Pulmonary Fibrosis (IPF)

## Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension

**Trial Status**  
Completed

**Trial Runs In**  
13 Countries

**Trial Identifier**  
NCT02951429 2015-005131-40  
MA29957

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced IPF and intermediate or high probability of Group 3 pulmonary hypertension (PH) who are on a stable dose of pirfenidone with demonstrated tolerability. Participants will be randomized to receive 1 year of treatment with either oral sildenafil or matching placebo while continuing to take pirfenidone.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02951429 2015-005131-40 MA29957**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 40 Years & <= 80 Years

**Healthy Volunteers**  
No

---